Article

Low-coverage whole-genome sequencing of plasma cell-free DNA to predict treatment response and progression-free survival in advanced NSCLC receiving EGFR-tyrosine kinase inhibitors or chemotherapy: A pilot prospective study

2026-04-21

Abstract excerpt

<title>Abstract</title> <p>Background: Accurately predicting treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC) remains a significant clinical challenge. While circulating tumor DNA (ctDNA) within plasma cell-free DNA (cfDNA) has emerged as a promising non-invasive biomarker, conventional targeted sequencing approaches require prior tumor genetic profiling and may miss the full spectr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 99581018-9524-5e6b-826d-44cc2d3eee1d
DOI: 10.21203/rs.3.rs-9258115/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Low-coverage whole-genome sequencing of plasma cell-free DNA to predict treatment response and progression-free survival in advanced NSCLC receiving EGFR-tyrosine kinase inhibitors or chemotherapy: A pilot prospective studyDOI 10.21203/rs.3.rs-9258115/v1Read

Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancerSemantic proximity Read

Genomic alterations and transcriptional phenotypes in circulating tumor DNA and matched metastatic tumorSemantic proximity Read

Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.Semantic proximity Read

Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer TherapySemantic proximity Read

Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.Semantic proximity Read

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.Semantic proximity Read

Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor.Semantic proximity Read

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumSemantic proximity Read

Cancer treatment monitoring using cell-free DNA fragmentomes.Semantic proximity Read

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read